再発性尿路感染症に対する予防的抗生物質が耐性リスクを増大 (Preventive antibiotics for recurrent UTIs increase the risk of antibiotic resistance)

2026-02-11 カーディフ大学

<関連情報>

• https://www.cardiff.ac.uk/news/view/3024384-preventive-antibiotics-for-recurrent-utis-increase-the-risk-of-antibiotic-resistance
• https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038%2825%2900178-5/fulltext

再発性尿路感染症および抗生物質耐性リスクを予防するための予防的抗生物質:SAILデータバンクによるターゲット試験エミュレーション Prophylactic antibiotics to prevent recurrent urinary tract infections and risk of antibiotic resistance: target trial emulation with the SAIL Databank

Leigh Sanyaolu, PhD ∙ Haroon Ahmed, PhD ∙ Victoria Best, MSc ∙ Prof Daniel Farewell, PhD ∙ Simon Schoenbuchner, PhD ∙ Prof Fiona Wood, PhD ∙ et al.
The Lancet Obstetrics, Gynaecology, & Women’s Health  Published: February 11, 2026
DOI:https://doi.org/10.1016/S3050-5038(25)00178-5

Summary

Background

Prophylactic antibiotics are recommended for the prevention of recurrent urinary tract infections (rUTIs) but can cause antibiotic resistance, a growing global concern. Estimates of the absolute risk of resistance with prophylactic antibiotic use are limited. We aimed to estimate the effect of prophylactic antibiotic use on antibiotic resistance in women with rUTIs.

Methods

We did a retrospective cohort study within the target trial framework using electronic health records of Welsh residents held by the Secure Anonymised Information Linkage (known as SAIL) Databank. We emulated a pragmatic trial of women aged 18 years or older with rUTIs, comparing the initiation of prophylactic antibiotics versus non-initiation. The primary outcome was hospital admission with an antibiotic-resistant infection by 52 weeks. Secondary outcomes were hospital admission with an antibiotic-resistant urine infection and uropathogen antibiotic resistance to one or more or two or more antibiotics. Using the survival probabilities, we calculated the risk, risk ratio, risk difference, and number needed to harm of each outcome for each treatment strategy by 52 weeks.

Findings

We identified 48 297 women in the SAIL Databank who were eligible for inclusion between Jan 1, 2015, and Dec 31, 2020, of whom 839 initiated prophylactic antibiotics. 616 women were admitted to hospital with an antibiotic-resistant infection by 52 weeks (thus, meeting the primary outcome). Prophylactic antibiotics did not increase the risk of hospital admission with an antibiotic-resistant infection by 52 weeks, with a risk of 1·4% (95% CI 1·3–1·5) in the non-antibiotic group and a risk of 1·9% (1·0–3·1) in the antibiotic prophylaxis group (risk ratio 1·41; 95% CI 0·74–2·24). Furthermore, the risk of admission with an antibiotic-resistant urine infection did not increase with prophylactic antibiotics (1·56, 0·76–2·49). However, prophylactic antibiotics increased the risk of uropathogen resistance to at least one antibiotic on urine culture (risk ratio 1·29, 95% CI 1·14–1·44) and resistance to two or more antibiotics on urine culture (1·57, 1·37–1·79).

Interpretation

In our target trial emulation, prophylactic antibiotic use did not increase the risk of hospital admission with an antibiotic-resistant infection or urine infection, but it did increase the risk of uropathogen antibiotic resistance and multidrug antibiotic resistance on urine culture. This study provides new data for the absolute risk and number needed to harm for individual-level antibiotic resistance that could be used to support shared decision-making discussions on rUTI prevention.

Funding

Health and Care Research Wales.